title: Clinical analysis of febrile neutropenia in urological anticancer chemotherapy: retrospective single center study.
abstract: OBJECTIVE
  The aims of this study were to clarify the frequency and prognosis of febrile neutropenia (FN) in patients who received urological anticancer chemotherapy.
  
  
  METHODS
  Between May 2005 and January 2010, 141 patients underwent urological anticancer chemotherapy at the Sapporo Medical University Hospital, Sapporo, Japan. They consisted of 124 men and 17 women aged 62 (range 16-80) years. The patients underwent a total of 626 treatment courses of urological anticancer chemotherapy.
  
  
  RESULTS
  Of the 626 urological anticancer chemotherapy courses, grades 3 and 4 neutropenia occurred in 451 (72.0 %) courses. FN developed in 57 (9.1 %) courses in which 7 (12.3 %) and 50 (87.7 %) patients were classified as high risk and low risk, respectively, according to the Multinational Association for Supportive Care in Cancer (MASCC) risk index scoring system. There was no anticancer chemotherapy-related death in either the high- or low-risk group. The frequencies of bacteria isolated from courses with FN were 0 and 10.0 % for the high- and low-risk groups, respectively.
  
  
  CONCLUSIONS
  According to the MASCC scoring system, there were fewer patients in the high-risk group than in the low-risk group in this study. There were no cases of anticancer chemotherapy-related death in either group. Therefore, urological anticancer chemotherapy can be conducted safely with the proper management of neutropenia and FN.
authors: Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan. nishiyan@sapmed.ac.jp.
authors: Naotaka
authors: N
authors: Nishiyama
authors: Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan. stakahas@sapmed.ac.jp.
authors: Satoshi
authors: S
authors: Takahashi
authors: Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan. koukai100@yahoo.co.jp.
authors: Takahiro
authors: T
authors: Mizuno
authors: Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan. teruhisa5963@yahoo.co.jp.
authors: Teruhisa
authors: T
authors: Uehara
authors: Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan. jirooh519@yahoo.co.jp.
authors: Jiro
authors: J
authors: Hashimoto
authors: Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan. kurimura@sapmed.ac.jp.
authors: Yuichirou
authors: Y
authors: Kurimura
authors: Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan. masumori@sapmed.ac.jp.
authors: Naoya
authors: N
authors: Masumori
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D064147:Febrile Neutropenia / Q000139:chemically induced* / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D014571:Urologic Neoplasms / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents
keywords: Anticancer chemotherapy; Febrile neutropenia; MASCC score; Urology
references: Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S32-7
references: 15250018
references: Clin Infect Dis. 2011 Feb 15;52(4):e56-93
references: 21258094
references: Clin Oncol (R Coll Radiol). 1994;6(4):232-6
references: 7986759
references: J Clin Oncol. 2000 Aug;18(16):3038-51
references: 10944139
references: J Clin Oncol. 2007 Jul 20;25(21):3158-67
references: 17634496
references: J Clin Oncol. 2005 Jun 20;23(18):4198-214
references: 15961767
references: Gan To Kagaku Ryoho. 2013 Jun;40(6):697-702
references: 23863646
references: Cancer Sci. 2011 Jun;102(6):1171-5
references: 21323791
references: Int Urol Nephrol. 1999;31(1):7-14
references: 10408296
references: J Infect Chemother. 2013 Apr;19(2):211-6
references: 23011233
references: Int J Urol. 2007 Oct;14(10):890-909
references: 17880286
references: J Clin Oncol. 2012 Apr 1;30(10):1107-13
references: 22370319
references: J Clin Oncol. 2000 Sep;18(17):3068-77
references: 11001674
references: Eur J Cancer. 2011 Jan;47(1):8-32
references: 21095116
references: Int J Urol. 1999 Feb;6(2):61-7
references: 10226809
references: J Clin Oncol. 2008 Jan 20;26(3):421-7
references: 18202419
references: Cancer. 1996 Mar 15;77(6):1193-7
references: 8635143